Lauren G. Grau

Lauren Grau guides clients through the evolving complexities of technology and intellectual property, with a focus on the life sciences, healthcare, digital health, artificial intelligence, energy, beauty, cosmetics, and consumer products sectors. With a background in biochemistry, she brings industry insight to her work in the life sciences space and leverages her experience as a former patent litigator to deliver practical, strategic advice tailored to clients’ transactional and IP needs.

Lauren advises emerging and public companies, as well as private equity firms, taking a holistic approach to mergers and acquisitions, divestitures, joint ventures, collaborations, licensing arrangements, strategic investments, and financing transactions. She also counsels clients on a broad range of commercial agreements, including collaboration, license, manufacturing and supply, distribution, co-promotion, development, and marketing agreements.

Lauren has been recognized as a “Rising Star” in the 2023–2025 editions of LMG Life Sciences for Licensing & Collaboration in the Financial & Corporate category, and by D Magazine as a “Best Lawyer in Dallas” in 2020, 2024, and 2025 for Corporate Law: Technology Transactions. She also received the “Outstanding Young Associate Award” in 2010 for her pro bono work with the Human Rights Initiative of North Texas.

Before law school, Lauren worked as a telecommunications engineer for a leading competitive local exchange carrier. During law school, she interned with the Honorable Harlin D. Hale of the U.S. Bankruptcy Court for the Northern District of Texas and served as head case notes and comments editor of the Houston Journal of International Law.

Transactional Experience: Life Sciences, Healthcare

• Smith & Nephew plc in its acquisition of Integrity Orthopaedics, Inc.
• Nektar Therapeutics in its US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital Partners.
• Access Healthcare, a leading revenue cycle management technology platform, in its growth investment from affiliates of New Mountain Capital, LLC.
• DaVita Inc., a leading provider of kidney care services, in its agreement to expand its international operations in Brazil and Colombia and its entry into Chile and Ecuador.
• Hoffmann-La Roche in its acquisition of Carmot Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing therapeutics for people living with metabolic diseases, for an upfront payment of US$2.7 billion and additional milestone payments of up to US$400 million.
• Novant Health, Inc. in its agreement with Tenet Healthcare Corporation (NYSE: THC) to acquire three Tenet hospitals and affiliated operations in South Carolina for approximately US$2.4 billion.
• Incyte Corporation in its acquisition of Villaris Therapeutics, Inc., a biopharmaceutical company focused on the development of novel antibody therapeutics.
• Myovant Sciences in its exclusive licensing agreement with Accord Healthcare, Ltd., to commercialize relugolix for the treatment of advanced, hormone-sensitive prostate cancer in the European Economic Area, United Kingdom, Switzerland, and Turkey.
• DaVita Inc. in its joint venture with Medtronic plc to form a new, independent, kidney care-focused medical device company.
• OMERS Private Equity in its agreement to sell its interest in Forefront Dermatology to global private markets firm Partners Group.
• CA Healthcare Acquisition Corp., a special purpose acquisition company focused on investing in a growth-oriented healthcare company, in its pending business combination with LumiraDx Limited, a next-generation point of care diagnostics testing company. The transaction has an implied pro forma equity value of US$3 billion.
• Steward Health Care System LLC in its sale of five hospitals and related hospital operations in Utah to HCA Healthcare, Inc.
• Steward Health Care System LLC in its acquisition of Tenet Healthcare Corporation’s five hospitals and related hospital operations in Florida’s Miami-Dade and southern Broward counties for approximately US$1.1 billion.
• GI Innovation on an exclusive regional licensing agreement with Simcere for the development and commercialization of a class of drug candidates for the treatment of solid tumors.
• Atomwise, a leader in using artificial intelligence (AI) for small molecule discovery, in a research collaboration agreement with Bridge Biotherapeutics, Inc. (KOSDAQ: 288330), a clinical stage biotech company, to launch up to 13 small molecule programs across multiple therapeutic areas using structure-based AI technology for drug discovery.
• Yuhan Corporation in its joint development and licensing agreement with Boehringer Ingelheim, for the development of dual agonist innovative drugs with the activity of GLP-1 and FGF21 to treat nonalcoholic steatohepatitis (NASH) and related liver disease.
• Yuhan Corporation in its licensing and collaboration agreement with Gilead Sciences, Inc. to co-develop novel therapeutic candidates for the treatment of patients with advanced fibrosis due to NASH.
• Yuhan Corporation in its licensing agreement with Janssen Biotech, Inc., a division of Johnson & Johnson, for the development, manufacturing, and commercialization of lazertinib, a non-small cell lung cancer drug candidate. Represented Nektar Therapeutics in its in multibillion dollar global strategic development and commercialization collaboration with Bristol-Myers Squibb Company (NYSE: BMY) for Nektar’s CD122-biased agonist, NKTR-214.
• Flatiron Health in its inaugural M&A transaction to acquire Protocol First, a software solutions provider focused on accelerating clinical research.
• Hoffmann-La Roche in its acquisition of Ignyta, Inc. (NASDAQ: RXDX), a cancer therapy company, for US$1.7 billion in cash, which LMG Life Sciences named as one of its “Deals of the Year.”
• GlaxoSmithKline on a novel public-private joint venture and collaboration with the University of North Carolina at Chapel Hill dedicated to seeking a cure for HIV.
• Genentech, a member of the Roche Group, in its agreement to acquire Seragon Pharmaceuticals, Inc., a biotechnology company focused on selective estrogen receptor degraders to treat hormone receptor-positive breast cancer, for a total amount of up to US$1.7 billion.
• Roche Molecular Systems in its acquisition of Genia Technologies, Inc., a DNA sequencing company, for up to US$350 million, and its acquisition of Bina Technologies, Inc., the creator of a big data platform for managing and processing next generation sequencing data.
• Darling Ingredients Inc. in its US$1.1 billion acquisition of Valley Proteins, Inc.

Transactional Experience: Beauty and Cosmetics, Consumer Products

• Beauty and cosmetic companies on IP ownership issues and manufacturing and supply agreements.
• OSEA Malibu in a strategic growth investment by General Atlantic.
• Olive & June, LLC in its US$240 million sale to consumer retail company Helen of Troy Limited.
• Carlin Consumer Health in its acquisition of PENETREX, a joint and muscle care consumer brand, from Wellbeam Consumer Health.
• TSG Consumer Partners and its portfolio companies in numerous matters, including the US$1.2 billion sale of portfolio company IT Cosmetics, LLC to L’Oreal.

Transactional Experience: Energy, Oil and Gas, Infrastructure

• Texon, L.P., a Houston, a Texas-based midstream service provider of butane blending and energy marketing, in its sale to Savage Enterprises LLC, a global provider of supply chain infrastructure and solutions.
• Enbridge Inc. in an infrastructure development agreement with Divert, Inc. to develop projects turning wasted food into renewable natural gas across the U.S. for up to more than US$1 billion of capital investments underpinned by long-term, take-or-pay contracts.
• Cresta Fund Management and Silverpeak Energy Partners in their agreement with San Joaquin Renewables to invest up to US$165 million to develop and construct a biomass-to-renewable natural gas project near McFarland, California.
• Enbridge, Inc. in its transaction with EnCap Flatrock Midstream to acquire Moda Midstream Operating, LLC for US$3 billion in cash.
• Eagle Materials Inc. in the sale of its Western Aggregates and Mathews Readymix operations to Teichert, Inc., a California-based construction company, for US$93.5 million.

Transactional Experience: Technology, Insurance, Financial Industry, Telecommunications, Other

• Kuvare Asset Management and Kuvare UK Holdings in the up to US$1 billion sale of Kuvare Asset Management to Blue Owl Capital Inc. (including potential earnout), and US$250 million preferred equity investment by Blue Owl Capital Inc. in Kuvare UK Holdings.
• Tenneco Inc., a portfolio company of funds managed by affiliates of Apollo Global Management, Inc., in its sale of Öhlins Racing to Brembo.
• National Western Life Group in its US$1.9 billion acquisition by an affiliate of Prosperity Life Group.
• Fleming Insurance Holdings, a portfolio company of Altamont Capital Partners in its strategic US$277 million acquisition of JRG Reinsurance Company.
• American National Group, Inc. as lead transaction counsel in its acquisition by Brookfield Asset Management Reinsurance Partners Ltd. in a transaction valued at US$5.1 billion.
• Bodega Latina Corporation in its acquisition of Smart & Final Holdings, Inc. from funds managed by affiliates of Apollo Global Management, Inc. (NYSE: APO) for approximately US$620 million.
• Safe Harbor Marinas in its sale to Sun Communities, Inc., a publicly traded REIT focused on manufactured housing and recreational vehicle communities, in a transaction for cash and equity valued at US$2.11 billion.
• Siris Capital Group, LLC in its US$654 million acquisition of Xura, Inc. (formerly Comverse).

• State Bar of Texas, Member
• Dallas Bar Association, Member
• DFW Women in IP